Granules India Ltd Share Price Today - Granules India Ltd Stock Price Live NSE/BSE

Granules India Ltd

NSE: GRANULES BSE: 532482

₹699.70

(-0.69%)

Thu, 07 May 2026, 03:25 pm

MTF 5xInvest in Granules India Ltd with 5x Leverage Buy with MTF

Market Cap174.85B

PE Ratio28.62

Dividend0.21

24.5K

Granules India Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
18236.61
Net Profit
501.52
P/B
3.18
Sector P/E
33.75
P/E
23.55
EV/EBITDA
12.81
Debt/Equity (Industry)
0.24
Interest Cover (Industry)
9.69
ROCE (Industry)
13.46
RONW (Industry)
12.65
ROE
14.45
ROCE
15.61
Debt/Equity
0.40
EPS (TTM)
24.32
Dividend Yield
0.24
Book Value
205.21
Interest Cover
7.39

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are thoroughly covered by earnings (13.2x coverage).
Dividends after 3 years are expected to be thoroughly covered by earnings (12x coverage).
Dividends per share have been stable in the past 10 years.
Granules India's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Granules India's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Granules India's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Granules India is expected to decrease over the next 2 years.
Granules India's earnings are expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).
Granules India's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	38.02	38.82	38.82	38.82	38.84
FII	15.31	13.55	14.09	13.24	15.15
DII	17.01	17.48	17.92	22.74	22.45
Public	29.66	30.15	29.17	25.20	23.57
Government	0	0	0	0	0

Technical Analysis

RSI

81.99

MACD

29.70

50 DMA

627.45

200 DMA

563.63

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	934.77	806.17	752.93	677.57	624.33	548.97	420.37
Fibonacci	806.17	757.04	726.69	677.57	628.44	598.09	548.97
Camarilla	735.07	723.28	711.49	677.57	687.91	676.12	664.34

Pivots Level: Classic

+257.20

934.77

+128.60

806.17

+75.37

752.93

677.57

Pivot Point

LTP: 743.50

-53.23

624.33

-128.60

548.97

-257.20

420.37

Moving Average

SMAEMA

Period

Value

10-EMA
708.25
20-EMA
684.38
30-EMA
666.76
50-EMA
643.52
100-EMA
612.47
200-EMA
581.25

Announcement Date	Purpose	Action	Ex Date
29 Apr 2026	agm
29 Apr 2026	board-meetings	Accounts, Quarterly Results, Final Dividend
23 Jan 2026	board-meetings	Quarterly Results
23 Dec 2025	egm
13 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
01 Jul 2025	dividend	Final Dividend - Rs. - 1.5	31 Jul 2025
28 May 2025	dividend	₹1.50 Dividend /Share	31 Jul 2025
28 May 2025	agm
30 Jun 2024	dividend	Annual General Meeting/Dividend - Rs 1.50 Per Share	31 Jul 2024
15 May 2024	agm

Granules India Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Divis Laboratories Ltd

Lupin Ltd

Granules India Ltd About

Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs).(Source : 202503-Annual Report Page No:134)

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1991

Headquarters

CEO

C Krishna Prasad

Employees

Contact

Website

http://www.granulesindia.com

investorrelations@granulesindia.com; mail@granules

Phone

91-40-69043500

Location

15th Floor Granules Tower, Botanical Garden Road Kondapur, Hyderabad, Telangana, 500084

Year	History
2020	Granules India arm got USFDA nod for Valganciclovir hydrochloride oral solution. Granules India received USFDA approval for Colchicine Tablets. Granules Pharmaceuticals Inc. got USFDA nod for Colchicine tablets. Granules India got tentative USFDA nod for Colchicine capsules for gout. Granules India got tentative nod from USFDA for expectorant tablets.
2021	Granules got USFDA nod for diabetes management drug. Granules India got USFDA nod for generic low blood potassium treatment capsules. Granules India received USFDA approval for Acetaminophen, Aspirin and Caffeine Tablets. Granules India received USFDA approval for Dofetilide capsules. Granules India's US unit got two observations from USFDA.
2022	Granules India received licenses from MPP to market Nirmatrelvir and Ritonavir. Granules Pharmaceuticals Inc. received ANDA approval for Bupropion Hydrochloride Extended-Release Tablets. Granules Pharmaceuticals Inc. received ANDA approval for Potassium Chloride for Oral Solution USP, 20 mEq.
2023	Granules India received USFDA approval for Losartan Potassium Tablets. Granules India forged a strategic partnership with Greenko ZeroC.
2024	Granules India Limited was honored with the Golden Peacock Award for Sustainability. Granules India received approval from the US health regulator to market a generic medication to treat major depressive disorder. The company received approval from the US Food & Drug Administration for Bupropion Hydrochloride extended-release tablets USP (SR) in strength of 100 mg, 150 mg, and 200 mg.

Client Name	Order Side	QTY	Avg Price	Date
L7 HITECH PRIVATE LIMITED	Buy	171737	587.41	14 Jan 2025
L7 HITECH PRIVATE LIMITED	Sell	1546000	577.85	14 Jan 2025
FIDELITY FUNDS.- INDIA FOCUS FUND	Sell	2924888	596.02	20 Dec 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	1995477	569.44	03 Dec 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	1995477	569.97	03 Dec 2024
SIXTEENTH STREET ASIAN GEMS FUND	Sell	1400000	547.14	26 Sept 2024
HRTI PRIVATE LIMITED	Buy	1509284	560.47	13 Sept 2024
HRTI PRIVATE LIMITED	Sell	1373686	561.33	13 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	2417342	606.13	12 Sept 2024
SHARE INDIA SECURITIES LIMITED	Buy	1787215	594.29	12 Sept 2024

Granules India Ltd News

Granules India FY26 Revenue Up 20%; Q4 Earnings Call Highlights

Granules India posted FY26 revenue of ₹53,656M (+20% YoY) and net profit of ₹5,950M (+19%). Q4 revenue rose 23% YoY. Management highlighted peptide CDMO progress, capex plans, and Gagillapur FDA readiness.

06 May 2026

companies

Granules India FY26 Results, Dividend, Q4 Call

Granules India's FY26 revenue rose 20% to ₹53,656 million with net profit of ₹5,950 million. The Board recommended a ₹1.75 dividend. Q4 revenue grew 23% YoY to ₹14,706 million.

05 May 2026

companies

Granules India Plans Controlled Substance Product Expansion

Granules India aims to launch 1-2 new controlled substance products annually over next 2-3 years, with 9 applications pending approval from Gagillapur site. Company targets positive peptide CDMO performance by FY27.

30 Apr 2026

companies

Granules India Board Approves FY26 Results, Recommends ₹1.75 Dividend

Board approved audited FY26 financial results and recommended final dividend of ₹1.75 per share. 35th AGM scheduled for August 6, 2026 with dividend record date July 30.

30 Apr 2026

companies

Granules India Board Approves FY26 Results, Recommends ₹1.75 Dividend

Board approved audited FY26 financial results and recommended final dividend of ₹1.75 per share. 35th AGM scheduled for August 6, 2026 with dividend record date July 30.

30 Apr 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800